Accepted for/Published in: JMIR Medical Informatics
Date Submitted: Jun 26, 2019
Open Peer Review Period: Jul 2, 2019 - Aug 13, 2019
Date Accepted: Jan 27, 2020
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Analyzing of the effect of age at diagnosis on the prognosis of inflammatory bowel disease (IBD) using common data model (CDM) : K-CDM network study
ABSTRACT
Background:
The Observational Health Data Sciences and Informatics network (OHDSI) is an international collaboration established to apply open-source data analytics to a large network of health databases, including the Korean common data model (K-CDM) network.
Objective:
We analyzed the factors associated with the prognosis of inflammatory bowel disease (IBD) in Korea using a CDM.
Methods:
We retrospectively analyzed K-CDM network database from 2005 to 2015. We transformed the EMR (electronic medical record) into CDM ver. 5.0 used in OHDSI. A worsened IBD prognosis was defined as initiation of therapy with biologic agents, including infliximab and adalimumab. To evaluate the effect of age at diagnosis on the prognosis of IBD, we used the log-rank test and Cox proportional hazards analysis.
Results:
A total of 3,480 patients (2,017 with ulcerative colitis [UC] and 1,463 with Crohn’s disease [CD]) were enrolled. The median follow up period was 109.5 weeks. In UC, EO-UC group statistical significantly showed lower event free survival (experiences of biologic agents) than LO-UC (p<0.001). In CD, EO-CD group showed lower event free survival (experiences of biologic agents) than LO-CD. In cox proportional hazard analysis, the odds ratio (OR) of EO-UC group on experience of biologic agents compared with LO-UC group was 2.3 (p=0.002). The OR of EO-CD group on experience of biologic agents compared with LO-CD was 5.4 (p=0.001).
Conclusions:
EO-IBD group showed more worsen prognosis than LO-IBD group in Korean IBD patients with successfully verifying CDM model in gastrointestinal research. Clinical Trial: non available
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.